| 1 | Technology | XLK | +28.1% |
| 2 | Energy | XLE | +26.1% |
| 3 | Materials | XLB | +13.1% |
| 4 | Real Estate | XLRE | +12.3% |
| 5 | Industrials | XLI | +11.5% |
| 6 | Consumer Staples | XLP | +10.5% |
| 7 | Utilities | XLU | +3.1% |
| 8 | Healthcare | XLV | -1.1% |
| 9 | Consumer Disc. | XLY | -1.5% |
| 10 | Financials | XLF | -2.9% |
| 11 | Communication | XLC | -4.5% |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. …
| Qtr | Date | EPS Est | Act | Δ | YoY | Rev Est | Act | Δ | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Q1 '26 | 5/6/26 | $0.27 | $0.18 | -33.3% | +500% | $0.2B | $0.2B | +2.0% | +70% |
| Q4 '25 | 2/26/26 | $0.34 | $0.14 | -58.8% | -7% | $0.2B | $0.2B | +0.4% | +78% |
| Q3 '25 | 11/3/25 | $0.22 | $2.43 | +10.0% | +12050% | $0.2B | $0.2B | +6.7% | +93% |
| Q2 '25 | 8/4/25 | $0.30 | $0.17 | -39.3% | +325% | $0.1B | $0.1B | -0.7% | +92% |
| Q1 '25 | 5/5/25 | $0.17 | $0.03 | -82.3% | +143% | $0.1B | $0.1B | +2.5% | +90% |